Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.

Literature DB >> 21998010

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.

David J FitzGerald¹, Alan S Wayne, Robert J Kreitman, Ira Pastan.

Abstract

To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21998010 PMCID： PMC3201758 DOI： 10.1158/0008-5472.CAN-11-1374

Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701

59 in total

1. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.

Authors: R J Kreitman; I Margulies; M Stetler-Stevenson; Q C Wang; D J FitzGerald; I Pastan
Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531

2. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.

Authors: R A Messmann; E S Vitetta; D Headlee; A M Senderowicz; W D Figg; J Schindler; D F Michiel; S Creekmore; S M Steinberg; D Kohler; E S Jaffe; M Stetler-Stevenson; H Chen; V Ghetie; E A Sausville
Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531

3. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Authors: P F Bross; J Beitz; G Chen; X H Chen; E Duffy; L Kieffer; S Roy; R Sridhara; A Rahman; G Williams; R Pazdur
Journal: Clin Cancer Res Date: 2001-06 Impact factor: 12.531

4. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Authors: R J Kreitman; W H Wilson; K Bergeron; M Raggio; M Stetler-Stevenson; D J FitzGerald; I Pastan
Journal: N Engl J Med Date: 2001-07-26 Impact factor: 91.245

5. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

Authors: Giuliana Salvatore; Richard Beers; Inger Margulies; Robert J Kreitman; Ira Pastan
Journal: Clin Cancer Res Date: 2002-04 Impact factor: 12.531

6. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.

Authors: R J Kreitman; W H Wilson; J D White; M Stetler-Stevenson; E S Jaffe; S Giardina; T A Waldmann; I Pastan
Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544

7. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

Authors: Anas Younes; Stella Kim; Jorge Romaguera; Amanda Copeland; Silvana de Castro Farial; Larry W Kwak; Luis Fayad; Frederick Hagemeister; Michelle Fanale; Sattva Neelapu; John M Lambert; Rodica Morariu-Zamfir; Sandrine Payrard; Leo I Gordon
Journal: J Clin Oncol Date: 2012-07-02 Impact factor: 44.544

8. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.

Authors: P L Amlot; M J Stone; D Cunningham; J Fay; J Newman; R Collins; R May; M McCarthy; J Richardson; V Ghetie
Journal: Blood Date: 1993-11-01 Impact factor: 22.113

9. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.

Authors: K J McGraw; M G Rosenblum; L Cheung; D A Scheinberg
Journal: Cancer Immunol Immunother Date: 1994-12 Impact factor: 6.968

10. Responses in refractory hairy cell leukemia to a recombinant immunotoxin.

Authors: R J Kreitman; W H Wilson; D Robbins; I Margulies; M Stetler-Stevenson; T A Waldmann; I Pastan
Journal: Blood Date: 1999-11-15 Impact factor: 25.476

64 in total

Review 1. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

Authors: Hagop Kantarjian; Deborah Thomas; Alan S Wayne; Susan O'Brien
Journal: J Clin Oncol Date: 2012-08-13 Impact factor: 44.544

2. A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling.

Authors: Jing Liu; Zhimin Gu; Ye Yang; Erik Wendlandt; Hongwei Xu
Journal: Hematol Oncol Date: 2014-01-09 Impact factor: 5.271

10. A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.

Authors: Hui Wei; Tapan K Bera; Alan S Wayne; Laiman Xiang; Simona Colantonio; Oleg Chertov; Ira Pastan
Journal: J Biol Chem Date: 2013-03-13 Impact factor: 5.157

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.

1. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.

2. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.

3. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

4. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

5. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

6. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.

7. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

8. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.

9. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.

10. Responses in refractory hairy cell leukemia to a recombinant immunotoxin.

Review 1. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

2. A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling.

Review 3. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.

Review 4. Getting across the cell membrane: an overview for small molecules, peptides, and proteins.

Review 5. Advances in targeted therapy for malignant lymphoma.

6. Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.

Review 7. Mechanisms of action of therapeutic antibodies for cancer.

Review 8. Antibody-based therapeutics for the treatment of human B cell malignancies.

Review 9. Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.

10. A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.